A Phase 3 interventional study of lerodalcibep in Heterozygous Familial Hypercholesterolemia, sponsored by LIB Therapeutics LLC. Completed at 7 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by LIB Therapeutics LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Hyperlipoproteinemia Type II with a site in Israel — 5 open to participants now, 5 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Israel.
Among the 11 studies in Hyperlipoproteinemia Type II with a site in Israel, this one is the 3rd largest by enrollment, is one of 2 that started in 2021, is one of 8 in phase 3, and was the 5th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →5 of the 11 studies in Hyperlipoproteinemia Type II with a site in Israel are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Israel, United States, Argentina and 20 more countries
Ages 6–11
Verve Therapeutics, Inc. · Sites in Israel, United States, Australia and 3 more countries
Ages 18–70
Novartis Pharmaceuticals · Sites in Israel, United States, Argentina and 23 more countries
Ages 2–100
LIB Therapeutics LLC · Sites in Israel, United States, India and 3 more countries
Ages 10+
LIB Therapeutics LLC · Sites in Israel, India, New Zealand and 2 more countries
Ages 6–17
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 9
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 478 is above the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 195 across the 11 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 6 most frequent:
LIB Therapeutics LLC is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
LIB Therapeutics LLC has 3 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Hyperlipoproteinemia Type II with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.
A randomized, double-blind, placebo-controlled, Phase 3 study of 24 weeks duration. Approximately 600 males and females aged ≥18 years with clinical or genetic heterozygous FH who fulfill the inclusion and exclusion criteria will be enrolled. Patients will be randomized in a 2:1 ratio to LIB003 (400 patients) or placebo (200 patients) administered SC Q4W (≤31 days). The study will consist of a Screening Period and a Treatment Period. The total study duration will be up to 35 weeks which includes up to an 11-week Screening Period (which may include up to a 8-week washout) and 24 weeks of study drug treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg (1.2 mL) SC Q4W
Drug: lerodalcibep
1.2 mL SC Q4W
Drug: lerodalcibep
300 mg Q4W
Also known as: LIB003
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24
Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
Time frame: Baseline and Week 24
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24
Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
Time frame: Baseline and Week 24
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24
Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Hopkins formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
Time frame: Baseline and Week 24
Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24
Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
Time frame: Baseline and Weeks 22 and 24
Change From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24
Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (measured by preparative ultracentrifugation). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
Time frame: Baseline and Week 24
Change From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24
Blood samples were collected at baseline and Week 24 to determine mean percent change in free PCSK9 concentrations. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
Time frame: Baseline and Week 24
Change From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24
Blood samples were collected at baseline and Week 24 to determine mean percent change in apo B. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline apo B value as covariate.
Time frame: Baseline to Week 24
Change From Baseline Compared to Placebo in Lipoprotein(a) at Week 24
Blood samples were collected at baseline and Week 24 to determine mean percent change in Lp(a). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline Lp(a) value as covariate.
Time frame: Baseline and Week 24
| Milestone | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Started | 319 | 159 |
| Completed | 306 | 155 |
| Not completed | 13 | 4 |
| Withdrew: Adverse event | 5 | 4 |
| Withdrew: Withdrawal by subject | 7 | 0 |
| Withdrew: Physician decision | 1 | 0 |
Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula at Week 24 | -52.32 ± 1.866 | 8.21 ± 2.609 |
Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (calculated by the Hopkins formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Level at Week 24 | -50.85 ± 1.846 | 8.35 ± 2.582 |
Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo in LDL-C Level Calculated by Friedwald Formula Using the Mean of Weeks 22 and 24 | -60.96 ± 1.625 | 7.31 ± 2.272 |
Blood samples were collected at baseline Week 22 and Week 24 to determine mean percent change in LDL-C (calculated by the Friedwald formula). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo in LDL-C Level Calculated by Hopkins Formula Using the Mean of Weeks 22 and 24 | -59.38 ± 1.615 | 7.51 ± 2.259 |
Blood samples were collected at baseline and Week 24 to determine mean percent change in LDL-C (measured by preparative ultracentrifugation). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo in LDL-C Level Measured by Preparative Ultracentrifugation at Week 24 | -49.65 ± 1.781 | 8.23 ± 2.491 |
Blood samples were collected at baseline and Week 24 to determine mean percent change in free PCSK9 concentrations. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline LDL-C value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo on Serum Unbound (Free) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentrations at Week 24 | -68.97 ± 2.299 | -3.97 ± 8.511 |
Blood samples were collected at baseline and Week 24 to determine mean percent change in apo B. Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline apo B value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo in Apolipoprotein B (Apo B) at Week 24 | -47.6 ± 1.57 | 4.6 ± 2.19 |
Blood samples were collected at baseline and Week 24 to determine mean percent change in Lp(a). Percent change from baseline determined using analysis of covariance (ANCOVA) model with treatment and CVD status as factors and baseline Lp(a) value as covariate.
| Percent Change | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Change From Baseline Compared to Placebo in Lipoprotein(a) at Week 24 | -19.40 ± 3.046 | 3.73 ± 4.267 |
Collected over From Baseline through week 24. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LIB003 (Lerodalcibep) | 0/318 (0%) | 10/318 (3.1%) | 230/318 (72.3%) |
| Placebo | 1/159 (0.6%) | 9/159 (5.7%) | 109/159 (68.6%) |
| Event | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| Angina pectorisCardiac disorders | 2/318 | 0/159 |
| Acute myocardial infarctionCardiac disorders | 0/318 | 1/159 |
| Myocardial infarctionCardiac disorders | 0/318 | 1/159 |
| Myocardial ischaemiaCardiac disorders | 0/318 | 1/159 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/318 | 1/159 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/318 | 1/159 |
| Alanine aminotransferase increasedInvestigations | 0/318 | 1/159 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/318 | 1/159 |
| Ischaemic strokeNervous system disorders | 0/318 | 1/159 |
| Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders | 0/318 | 1/159 |
| Event | LIB003 (Lerodalcibep) | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 35/318 | 17/159 |
| Injection site reactionGeneral disorders | 32/318 | 2/159 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/318 | 13/159 |
| Injection site erythemaGeneral disorders | 23/318 | 1/159 |
| Upper respiratory tract infectionInfections and infestations | 18/318 | 11/159 |
| NasopharyngitisInfections and infestations | 16/318 | 3/159 |
| Urinary tract infectionInfections and infestations | 10/318 | 8/159 |
| HypertensionVascular disorders | 15/318 | 6/159 |
| GastroenteritisInfections and infestations | 14/318 | 4/159 |
| HeadacheNervous system disorders | 12/318 | 5/159 |
| Age, Categorical(Participants) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 259 | 130 | 389 |
| >=65 years | 60 | 29 | 89 |
| Sex: Female, Male(Participants) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| Female | 164 | 83 | 247 |
| Male | 155 | 76 | 231 |
| Ethnicity (NIH/OMB)(Participants) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 315 | 157 | 472 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race/Ethnicity, Customized(Participants) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| White | 273 | 143 | 416 |
| Black or African American | 25 | 12 | 37 |
| Asian | 21 | 4 | 25 |
| Region of Enrollment(Participants) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| South Africa | 174 | 81 | 255 |
| Turkey | 37 | 29 | 66 |
| New Zealand | 38 | 22 | 60 |
| Norway | 26 | 7 | 33 |
| Spain | 10 | 12 | 22 |
| India | 14 | 3 | 17 |
| Israel | 10 | 2 | 12 |
| Canada | 6 | 2 | 8 |
| United States | 4 | 1 | 5 |
| Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Friedewald Formula (mg/dL)(mg/dL) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| Mean | 152.1 ± 67.42 | 146.4 ± 56.87 | 150.2 ± 64.10 |
| Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Hopkins Formula (mg/dL)(mg/dL) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| Mean | 153.5 ± 67.28 | 147.2 ± 56.77 | 151.4 ± 63.98 |
| Baseline Low-density Lipoprotein Cholesterol (LDL-C) by Preparative Ultracentrifugation (mg/dL)(mg/dL) | LIB003 (Lerodalcibep) | Placebo | Total |
|---|---|---|---|
| Mean | 149.3 ± 64.10 | 144.7 ± 53.66 | 147.8 ± 60.81 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Jul 2023, 27 months.
Results were first posted in Sep 2026, 3 years 1 month after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 27 months is above that.
Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lerodalcibep
Hyperlipoproteinemia Type II →
LIB Therapeutics LLC